Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Dermatology

Free Subscription 06.07.2026 1 Am J Dermatopathol 77 BMC Cancer 4 Br J Dermatol 2 Cancer Res 2 Hum Mutat 1 Int J Dermatol 6 J Dermatol 2 J Invest Dermatol 1 Plast Reconstr Surg 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. FIKE H, Li S, Farnham T, Siref A, et al
   Herpetic Whitlow in Association With a Cutaneous Infiltrate of Chronic Lymphocytic Leukemia.
   Am J Dermatopathol. 2026 Jun 30. doi: 10.1097/DAD.0000000000003357.
   PubMed        
   
   

   
   BMC Cancer

2. TEPETAM H, Varan MP, Alomari O, Yildirim S, et al
   Cardiotoxicity perspective on the concurrent use of anti-HER2 agents and hypofractionated versus conventional fractionated locoregional radiotherapy in breast cancer.
   BMC Cancer. 2026 May 11. doi: 10.1186/s12885-026-16160.
   PubMed         Abstract available
   
   
3. IHLAMUR M, Demi?rci?oglu A, Zorba AP, Abamor ES, et al
   Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.
   BMC Cancer. 2026 May 9. doi: 10.1186/s12885-026-16143.
   PubMed         Abstract available
   
   
4. NAKAUCHI C, Masunaga N, Eguchi Y, Tanei T, et al
   Discordance between IHC/FISH and RNA expression-based assessment of ER/HER2 status, and its prognostic impact assessed by propensity score matching.
   BMC Cancer. 2026;26:808.
   PubMed         Abstract available
   
   
5. AKPALAMUT D, Ellez HI, Atag E, Aktepe OH, et al
   Prognostic factors and survival in elderly breast cancer patients: roles of age, stage and inflammatory markers.
   BMC Cancer. 2026 May 7. doi: 10.1186/s12885-026-16142.
   PubMed         Abstract available
   
   
6. BORG M, Farver-Vestergaard I, Hilberg O, Steed L, et al
   Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16095.
   PubMed        
   
   
7. ERRIHANI H, Berrada N, El Bachiri M, Jouhadi H, et al
   Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16005.
   PubMed        
   
   
8. QUISENAERTS T, Van Der Auwera I, Poortmans P, Reynders D, et al
   Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol.
   BMC Cancer. 2026;26:743.
   PubMed         Abstract available
   
   
9. KESKIN GSY, Turgut GG, Yildirim G, Tuzun EK, et al
   Prognostic value of cachexia index in HR +/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16078.
   PubMed        
   
   
10. PERERA R, Wijethunga D, Perera M, Abeywickrama C, et al
    Quality of life in breast cancer survivors: insights from a university hospital in Sri Lanka.
    BMC Cancer. 2026 Apr 25. doi: 10.1186/s12885-026-16023.
    PubMed        
    
    
11. PARK R, Lee EY, Kang JW, Jun S, et al
    Effect of early exercise on functional recovery and surgical outcomes after post-mastectomy breast reconstruction: study protocol for a randomized clinical trial.
    BMC Cancer. 2026;26:731.
    PubMed         Abstract available
    
    
12. ALBALAWI ES, Qayyum J, Qayyum J
    Population-specific MicroRNA biomarker discovery in breast ductal carcinoma via explainable graph neural multi-omics modeling.
    BMC Cancer. 2026;26:721.
    PubMed         Abstract available
    
    
13. ZHOU Y, Wang X, Li F, Qin H, et al
    MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.
    BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-15956.
    PubMed        
    
    
14. LIM MSH, Tan SSN, Wan Maharuddin IB, Wan Ali SAB, et al
    Breast cancer survival rates in Sarawak, Malaysia: a central referral centre study.
    BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16065.
    PubMed        
    
    
15. MATKOWSKI R, Abrahamowska M, Michalowska D, Chrusciel A, et al
    Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients: insights from a regional genetic testing cohort from Lower Silesia.
    BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16017.
    PubMed        
    
    
16. YANG X, Hao Z, Yao R, Zhang J, et al
    High TLG measured by PET/CT is associated with worse PFS in patients with advanced HR+ breast cancer treated by abemaciclib combined with endocrine therapy.
    BMC Cancer. 2026 Apr 20. doi: 10.1186/s12885-026-16032.
    PubMed        
    
    
17. XIANG Z, Qi X, Liu Y, Zhang F, et al
    Efficacy and safety of ultra-hypofractionated post-operative radiation therapy for breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Apr 18. doi: 10.1186/s12885-026-16020.
    PubMed        
    
    
18. NASCIMENTO DW, Filassi JR, Cunha AFT, Goncalves R, et al
    Impact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil.
    BMC Cancer. 2026 Apr 16. doi: 10.1186/s12885-026-15994.
    PubMed        
    
    
19. LIU Y, He T, Tang C, Li F, et al
    Single-cell and spatial transcriptome analysis of breast cancer tumor-associated fibroblast heterogeneity and its mediated remodeling of the tumor microenvironment.
    BMC Cancer. 2026 Apr 15. doi: 10.1186/s12885-026-16003.
    PubMed        
    
    
20. WIJAYALATHGE H, Peiris K, Jayarajah U, Gunasekara S, et al
    Quality of life following completion of surgery and chemoradiation among Sri Lankan women with breast cancer.
    BMC Cancer. 2026 Apr 13. doi: 10.1186/s12885-026-15991.
    PubMed        
    
    
21. CONG B, Hou C, Shan C, Sun S, et al
    Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15983.
    PubMed        
    
    
22. KOCHI A, Kashiwagi S, Nakada K, Gose A, et al
    Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15948.
    PubMed        
    
    
23. WALBAUM B, Acevedo F, Segui E, Martinez-Saez O, et al
    Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.
    BMC Cancer. 2026 Apr 10. doi: 10.1186/s12885-026-15998.
    PubMed        
    
    
24. QI WX, Ou D, Cao L, Li S, et al
    The PRINCE-BC trial: precision regional irradiation of nodal stations for clinical evaluation of high-risk pN0 breast cancer - a phase III, open-label, randomized controlled trial.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15971.
    PubMed        
    
    
25. ANSARI H, Hajigholami A, Aslani H, Hajigholami A, et al
    Preliminary modeling of brain metastases in breast cancer: a neural network approach to risk factor analysis.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15954.
    PubMed        
    
    
26. NISHIKAWA M, Kashiwagi S, Kochi A, Watanabe C, et al
    Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15913.
    PubMed        
    
    
27. BARJIJ I, Lamsyah O, Kdadri S, Lkhoyaali S, et al
    Spatial and temporal intratumoral heterogeneity in breast cancer: a systematic and conceptual review of single-cell and spatial omics studies.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15928.
    PubMed        
    
    
28. XU H, Wang Y, Sa Q, Zhou Y, et al
    Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15947.
    PubMed        
    
    
29. WANG Z, Cao Y, Wang Q, Wang L, et al
    Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.
    BMC Cancer. 2026;26:651.
    PubMed         Abstract available
    
    
30. HU J, Xiong Z, Wang X
    Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15941.
    PubMed        
    
    
31. HUANG Z, Muritti C, Sieuwerts A, de Weerd V, et al
    Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15876.
    PubMed        
    
    
32. VERDUIN RJT, van den Hurk CJG, van Maurik IS, Nota NM, et al
    Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial.
    BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15905.
    PubMed        
    
    
33. FAN M, He S, Wan C, Zhang J, et al
    Joint synthesis of longitudinal MRI and enhanced prediction of neoadjuvant chemotherapy response in breast cancer: a multicohort study.
    BMC Cancer. 2026 Mar 24. doi: 10.1186/s12885-026-15889.
    PubMed        
    
    
34. GUPTA R, Gopalsamy IK, Nadukkandy AS, Singh A, et al
    GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/beta-catenin/Cyclin D1 axis in breast cancer.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15821.
    PubMed        
    
    
35. ATTAH DA, Nsaful J, Sefogah PE
    Coping with breast cancer in Ghana: a qualitative study of women's lived experiences following breast cancer diagnosis.
    BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15857.
    PubMed        
    
    
36. FATIREGUN OA, Sutradhar R, Podolsky S, Eisen A, et al
    Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15693.
    PubMed        
    
    
37. LIU S, Li Y, Shen Y, Mao Q, et al
    Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15861.
    PubMed        
    
    
38. SENEVIRATHNA K, Francis AH, Pirzada M, Mahakapuge TAN, et al
    An exploratory ATR-FTIR spectroscopic study of serum protein structural alterations in oral squamous cell carcinoma and oral potentially malignant disorders.
    BMC Cancer. 2026;26:539.
    PubMed         Abstract available
    
    
39. AMUJI DN, Iweala EEJ
    Association of MET gene polymorphisms with breast cancer risk in Nigerian patients: a case-control study.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15844.
    PubMed        
    
    
40. ARRARAS JI, Illarramendi JJ, Manterola A, Giesinger JM, et al
    The EORTC updated breast cancer quality of life questionnaire EORTC QLQ-BR42: A psychometric study with Spanish patients.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15831.
    PubMed        
    
    
41. GUO HL, Xie HY, Jiang CL, Weng CF, et al
    Surface-guided radiation therapy combined with real-time position management-guided deep inspiratory breath-hold radiotherapy for left breast cancer.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15846.
    PubMed        
    
    
42. OZCAN D, Nielsen PS, Alsner J, Nielsen MH, et al
    Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15859.
    PubMed        
    
    
43. MAVILI HS, Atmis O, Pehlivan FS, Ekinci F, et al
    Stromal hypoxia and autophagy signatures as indicators of pathologic response in triple-negative breast cancer.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15860.
    PubMed        
    
    
44. GUCLU T, Tanriverdi O, Bayrakci I, Demir B, et al
    Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer).
    BMC Cancer. 2026 Mar 11. doi: 10.1186/s12885-026-15842.
    PubMed        
    
    
45. GUTIERREZ-GONZALEZ A, Maciel-Cruz EJ, Reynoso-Noveron N, Mohar-Betancourt A, et al
    Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15808.
    PubMed        
    
    
46. XIE Z, Wang K, Liu J, Hong Z, et al
    Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.
    BMC Cancer. 2026;26:439.
    PubMed         Abstract available
    
    
47. UGUZTEMUR E, Dogan M
    Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer.
    BMC Cancer. 2026 Feb 27. doi: 10.1186/s12885-026-15795.
    PubMed        
    
    
48. LEE SF, Cokelek M, Yip PL, Bayley K, et al
    Dosimetric comparison of IMRT and VMAT with deep inspiration breath hold or free breathing for right-sided whole breast irradiation.
    BMC Cancer. 2026;26:429.
    PubMed         Abstract available
    
    
49. FAN Y, Sahoo S, Jolly MK, George JT, et al
    Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-026-15691.
    PubMed        
    
    
50. TANG X, Wang T, Shi H, Zhang M, et al
    Breast cancer detection using microscopic images based on composition features.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-025-15456.
    PubMed        
    
    
51. EDET B, Sarimiye FO, Essien E, Lu B, et al
    A cross-sectional study of coping strategies among a sample of women with breast cancer in South-South, Nigeria.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15770.
    PubMed        
    
    
52. BROWNSON-SMITH R, Carr J, Orange ST, Cresti N, et al
    Longitudinal assessment of chemotherapy-induced peripheral neuropathy in women undergoing taxane-based treatment for breast cancer: a prospective observational study.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15750.
    PubMed        
    
    
53. DENG Y, Huang W, Zeng T, Gao Y, et al
    CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15713.
    PubMed        
    
    
54. HOSSAIN I, Ivy SC, Islam MS, Shahriar M, et al
    Evaluation of ERCC4 (XPF) gene rs6498486 polymorphism and its potential role in breast cancer risk among Bangladeshi women.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15739.
    PubMed        
    
    
55. CONTRERAS-SANCHEZ SE, Doubova SV, Grajales-Alvarez R, Villalobos-Valencia R, et al
    Effectiveness of a digital health intervention on the supportive care needs and quality of life in Mexican patients with breast cancer: a randomized clinical trial.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15724.
    PubMed        
    
    
56. LIAO H, Li H, Qu Y, Tang L, et al
    IL-8 positive cancer-associated fibroblasts drive breast cancer progression and immune evasion: insights from GWAS and single-cell transcriptomics.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15716.
    PubMed        
    
    
57. AROMAA-HAYHA A, Auvinen P, Malila N, Kataja V, et al
    Nonadherence to changing guidelines in early breast cancer over two decades.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15731.
    PubMed        
    
    
58. ZHANG J, Dai C, Wang S, Chen Y, et al
    An evaluation model of chemotherapy efficacy in breast cancer based on combined serum CA15-3, CEA, and CYFRA 21 - 1.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15687.
    PubMed         Abstract available
    
    
59. GAO Y, Gong J, Yang Y, Luo Y, et al
    Stratified prediction of HER2 status in breast cancer by integrating intratumoral and peritumoral radiomics from DCE-MRI.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15688.
    PubMed        
    
    
60. KUBECZKO M, Polakiewicz-Gilowska A, Swiderska K, Mianowska-Malec M, et al
    Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15594.
    PubMed        
    
    
61. MAYBERRY SA, Hsu PC, Lin HY, Rogers LJ, et al
    Association of DNA methyltransferase polymorphisms with breast cancer: a nested case?control study of the Arkansas Rural Community Health study.
    BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15695.
    PubMed        
    
    
62. ZHANG L, Sun F, Wang X, Zhao W, et al
    Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15632.
    PubMed        
    
    
63. OZTURK HA, Koc M, Okyay RA, Ozturk DD, et al
    Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15696.
    PubMed         Abstract available
    
    
64. LAMY C, Laurent L, Choussy O, Pouget N, et al
    SCANDARE: an institutional dynamic prospective interventional biobanking study.
    BMC Cancer. 2026;26:330.
    PubMed         Abstract available
    
    
65. CAMPONE M, Frenel JS, Kiver VII, Woeckel A, et al
    Treatment patterns and clinical outcomes in chemotherapy-treated patients with HR+/HER2- metastatic breast cancer using real-world data in France and Germany.
    BMC Cancer. 2026 Feb 3. doi: 10.1186/s12885-026-15611.
    PubMed        
    
    
66. BRANDSTETTER LS, Grau A, Muller-Reiter M, Salmen J, et al
    Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15641.
    PubMed        
    
    
67. TAO R, Liu B, Gao S, Zhang J, et al
    The role of CD26 in breast cancer and its pan-cancer analysis.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15656.
    PubMed         Abstract available
    
    
68. SAFAVI A, Mohammadzadeh N, Kaviani A, Dadashi A, et al
    Axillary staging in post-neoadjuvant chemotherapy breast cancer patients: prognostic analysis and validation of axillary nodal metrics and comparison of pathological node staging versus the lymph node ratio systems in a 169-case series.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15564.
    PubMed        
    
    
69. AWADA Z, Kazmi N, Jones HJ, Lewis SJ, et al
    The causal association between systolic blood pressure and breast cancer: a two sample Mendelian randomization study.
    BMC Cancer. 2026 Jan 22. doi: 10.1186/s12885-025-15513.
    PubMed        
    
    
70. AIKELAIMU A, Li W, Kaicaier M, Liu S, et al
    Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-025-15521.
    PubMed        
    
    
71. ZHANG C, Li S, Ren J, Wen X, et al
    Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15561.
    PubMed        
    
    
72. CHEN BA, Qin WH, Chen HB, Yang QH, et al
    The effect of exercise intervention on IGF axis and metabolic markers regulation in breast cancer patients: a systematic review with pairwise, network, and dose-response meta-analyses.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15475.
    PubMed        
    
    
73. MASHAYEKH Z, Fard RF, Vallian S
    Noncoding RNAs and DNA methylation as epigenetic modulators of breast cancer: mechanisms and clinical perspectives in the Iranian population, a systematic review.
    BMC Cancer. 2025 Dec 20. doi: 10.1186/s12885-025-15430.
    PubMed        
    
    
74. LI X, Li C, Jiang L, Zheng D, et al
    Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.
    BMC Cancer. 2025;26:66.
    PubMed         Abstract available
    
    
75. KITONGO E, Segawa ES, Joyce N, Valeria N, et al
    Mammographic findings and BI-RADS concordance in women attending a community outreach program in Uganda.
    BMC Cancer. 2025;26:15.
    PubMed         Abstract available
    
    
76. LI J, Liu J, Cai B, Yang C, et al
    Association of estimated glucose disposal rate with all-cause and breast cancer-specific mortality in US breast cancer survivors: a population-based study.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15340.
    PubMed         Abstract available
    
    
77. LIU Y, Ren T, Chen X, He Q, et al
    Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1535.
    PubMed        
    
    
78. SALHI I, Bannoura S, Abedaljawwad O, Salah Z, et al
    Cutaneous and mucosal melanoma among the Palestinian population: a retrospective clinicopathological study with comparative regional context.
    BMC Cancer. 2026 Jun 29. doi: 10.1186/s12885-026-16393.
    PubMed         Abstract available
    
    

    
    Br J Dermatol

79. BJURLING J, Forsberg LA
    Does loss of chromosome Y in blood contribute to the sex disparity of dermatitis and eczema at older ages?
    Br J Dermatol. 2026 Jul 4:ljag270. doi: 10.1093.
    PubMed        
    
    
80. STEIN GOLD L, Armstrong AW, Soung J, Vender RB, et al
    Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.
    Br J Dermatol. 2026 Jul 3:ljag264. doi: 10.1093.
    PubMed         Abstract available
    
    
81. RAN NA, Ruiz ES
    Improving Prognostication for Cutaneous Squamous Cell Carcinoma.
    Br J Dermatol. 2026 Jul 2:ljag271. doi: 10.1093.
    PubMed        
    
    
82. SIEGFRIED EC, Baselga E, de Graaf M, Simpson EL, et al
    Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.
    Br J Dermatol. 2026 Jul 1:ljag261. doi: 10.1093.
    PubMed        
    
    

    
    Cancer Res

83. WONG H, Korsakova A, Wu AJ, Kularatnarajah L, et al
    An Analytical Framework Characterizes the Biological Processes that Shape Copy Number-Based Genome Instability Patterns in Breast Cancer.
    Cancer Res. 2026 Apr 9. doi: 10.1158/0008-5472.CAN-25-2569.
    PubMed         Abstract available
    
    
84. GAO A, Khatri PH, Ma G, Liu P, et al
    Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.
    Cancer Res. 2026 Mar 26. doi: 10.1158/0008-5472.CAN-25-4701.
    PubMed         Abstract available
    
    

    
    Hum Mutat

85. MAO C, Chen G, Tang J, Leng R, et al
    Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1.
    Hum Mutat. 2026;2026:6776070.
    PubMed         Abstract available
    
    
86. LUO Z, Shi Y, Zhu B, Huang Q, et al
    Pharmacovigilance Signal Detection and Mutually Exclusive Driver Mutations of the PI3K/AKT Pathway in Breast Cancer Treated With Capivasertib.
    Hum Mutat. 2026;2026:9532614.
    PubMed         Abstract available
    
    

    
    Int J Dermatol

87. MEVES A
    SENTINOLD and the Challenge of Meaningful Risk Prediction in Melanoma.
    Int J Dermatol. 2026 Jul 3. doi: 10.1111/ijd.70572.
    PubMed        
    
    

    
    J Dermatol

88. CHEN YW, Chen YH, Yen TH, Chen YJ, et al
    Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real-World Study.
    J Dermatol. 2026 Jul 3. doi: 10.1111/1346-8138.70369.
    PubMed         Abstract available
    
    
89. WATANABE T, Yamakawa K, Kobayashi M, Saigusa Y, et al
    Risk Factors for Cutaneous Immune-Related Adverse Events in the Japanese Population: A Retrospective Single-Center Cohort Study.
    J Dermatol. 2026 Jul 2. doi: 10.1111/1346-8138.70370.
    PubMed         Abstract available
    
    
90. KATAOKA Y, Etoh T, Saeki H, Katoh N, et al
    Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.
    J Dermatol. 2026 Jul 2. doi: 10.1111/1346-8138.70345.
    PubMed         Abstract available
    
    
91. CHIHIRO I, Hagino T, Takahashi Y, Yoneyama M, et al
    Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.
    J Dermatol. 2026 Jul 1. doi: 10.1111/1346-8138.70367.
    PubMed         Abstract available
    
    
92. USUI M, Ikuno Y, Kobayashi S, Yamada M, et al
    Sparing of the Nipple-Areolar Complex and Periareolar Skin as a Diagnostic Clue for Radiation-Induced Morphea of the Breast.
    J Dermatol. 2026 Jul 1. doi: 10.1111/1346-8138.70368.
    PubMed        
    
    
93. DURSUN P, Saribas Yildirim AN, Yazici A
    Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case-Control Study.
    J Dermatol. 2026 Jun 28. doi: 10.1111/1346-8138.70372.
    PubMed         Abstract available
    
    

    
    J Invest Dermatol

94. DUZ T, Torocsik D, Momnougui SME, Oubounyt M, et al
    An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.
    J Invest Dermatol. 2026 Jul 2:S0022-202X(26)02662.
    PubMed         Abstract available
    
    
95. GHAHARI N, Zheng L, Kuppanda PM, Chandra SS, et al
    Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.
    J Invest Dermatol. 2026 Jun 29:S0022-202X(26)02660.
    PubMed        
    
    

    
    Plast Reconstr Surg

96. LYNN JV, Baffour-Addo K, Lane ME, Hsu JJ, et al
    "Wise Pattern Skin-Sparing Mastectomy with Two-Stage Implant-Based Breast Reconstruction Among Patients with Breast Ptosis".
    Plast Reconstr Surg. 2026 Jun 29. doi: 10.1097/PRS.0000000000013290.
    PubMed         Abstract available
    
    

    
    PLoS One

97. CHENG Y, Jiang YN, Zhang Q
    Navigating ethical waters: The impact of ethical judgment, norms, and CSR skepticism on CSR engagement and purchasing intention in a breast cancer campaign.
    PLoS One. 2026;21:e0352994.
    PubMed         Abstract available
    
    
98. KAKHKI NR, Hegedus Z, Tovari J, Mirzahosseini A, et al
    Metabolic profiling of human melanoma cell lines with high and low metastatic capacity by 1H-NMR spectroscopy.
    PLoS One. 2026;21:e0352639.
    PubMed         Abstract available
    
    
99. MOHTAR MA, Fessart D, Yuh Cai C, Zahari S, et al
    Genetic regulatory axis between AGR2 and ESR1 promotes breast cancer progression.
    PLoS One. 2026;21:e0351873.
    PubMed         Abstract available
    
    
100. ISHII H, Nishiyama K, Nakahara A, Tamori S, et al
     Cell-cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer.
     PLoS One. 2026;21:e0352254.
     PubMed         Abstract available
     
     
101. SIROTICH E, Lowry W, Wang SY, Jurgens M, et al
     Incidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis.
     PLoS One. 2026;21:e0351646.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum